BIO Leads New Group Pushing For Antibiotic Incentives, DISARM Act

By David Roza / August 23, 2019 at 4:04 PM
A new group led by the Biotechnology Innovation Organization (BIO) is urging Congress to create additional incentives for drug and biologic makers to develop innovative antibiotics, starting with passage of the Medicare add-on payments included in the Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. The group, Working to Fight AMR, includes representatives from Merck, Novo Holdings, Paratek Pharmaceuticals and Boston University School of Law. Greg Frank, the director of the group and director of infectious...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.